Background
==========

Avascular necrosis (AVN) of the femoral head (FH) is a debilitating and painful disease with multiple etiologic risk factors \[[@B1]-[@B4]\]. These include, but are not limited to, corticosteroid use \[[@B1],[@B3]-[@B6]\], alcohol abuse \[[@B1]-[@B4]\], previous trauma \[[@B1],[@B3]\], hemoglobinopathy \[[@B7]\], Gaucher's disease and coagulopathies \[[@B8]\]. The onset of AVN may also be idiopathic \[[@B7]\]. AVN of the FH most commonly affects younger or middle aged adults \[[@B2],[@B9],[@B10]\]. Disease progression commonly leads to collapse of the affected FH and ultimately, development of osteoarthritis \[[@B1],[@B3],[@B4],[@B7],[@B11],[@B12]\]. Outcomes of THA for these younger and more active patients have been poor, primarily due to the limited lifetime and durability of total hip arthroplasty (THA) \[[@B6],[@B10],[@B11]\]. As a result, there has been an increased focus on early-interventions for AVN, aimed at preservation of the native articulation \[[@B6],[@B12]\]. Core decompression (CD) is currently the most widely accepted treatment for early-stage AVN of the FH; however, due to limited efficacy, its use has been debated \[[@B12]\]. The development of safe, cost-effective, and potentially minimally invasive joint preserving treatments for early stage (precollapse) AVN merits further investigation.

Several studies, both clinical and pre-clinical, have demonstrated the efficacy of stem cells (SC) for the treatment of AVN of the FH \[[@B1],[@B3],[@B11],[@B13]-[@B15]\]. SC can be obtained from a variety of sources, including autologous bone marrow \[[@B2],[@B4],[@B10],[@B11],[@B16],[@B17]\], adipose tissue \[[@B10]\] and dental-pulp \[[@B4]\]. SC have been shown to promote bone formation \[[@B4],[@B6],[@B11],[@B12]\] and neovascularization \[[@B6],[@B11]\] in vitro. Additionally, patients treated with SC in conjunction with CD demonstrated significant improvements in Harris Hip Scores (HHS) \[[@B15]\] as well as decreased hip pain and symptoms compared to those treated with CD alone \[[@B2]\]. Yan et al. documented that stem cells implanted into the necrotic FH not only survive, but thrive and proliferate \[[@B15]\]. Although the pathogenesis of AVN is unclear \[[@B17]\] many hypothesize that SC work to improve early stage AVN potentially as a function of their critical role in the regulation and improvement of osteogenesis and angiogenesis \[[@B11],[@B12]\]. Furthermore, it is thought that mesenchymal SC implanted into the necrotic FH may differentiate into osteoblasts or vascular endothelial cells, thereby promoting bone repair and regeneration \[[@B12]\]. Despite encouraging results in preclinical (basic science) and clinical studies, improvements in hip survivorship or time to THA has not been uniformly reported and remains controversial \[[@B2],[@B8],[@B14]\].

The purpose of our study was to perform a systematic review of the current medical literature on the treatment of early stage AVN of the FH using SC implanted via CD. We examined both preclinical studies and clinical studies. We reported bone healing outcomes (histologic and imaging outcomes) from preclinical papers and all examined outcomes from available clinical papers.

Methods
=======

Eligibility criteria
--------------------

Manuscripts were deemed eligible for our review if they evaluated treatment of early stage AVN of the FH with SC implanted via CD. We defined early stage AVN as precollapse of the FH. Both clinical and preclinical manuscripts were selected. For clinical trials, we included studies on patients age \> 18. All types of clinical studies were eligible for inclusion to this review. Studies of all languages were eligible for inclusion to this review. For studies reporting on the same group of patients at multiple follow up periods, the most recent publication was used in this review. For preclinical studies, manuscripts were eligible if they examined bone healing either histologically, or by imaging techniques. If studies examined other treatments such as vascularized fibular grafting or bone morphogenic proteins, they were excluded unless the data on SC and CD were presented separately from the other treatments, to allow us to examine the effect of SC specifically.

Study identification
--------------------

A systematic, computerized search for potential manuscripts was performed by three independent reviewers (HE, SM, RL). Pubmed (−July 2012), Ovid Medline (−July 2012) and EMBASE (−July 2012) databases were used to identify studies. Key words used for the search were: AVN or avascular necrosis or osteonecrosis AND stem cells; AVN or avascular necrosis or osteonecrosis AND autologous bone marrow. Abstracts were retrieved for all manuscripts considered relevant by title. Abstracts were independently reviewed and any disagreements were resolved by discussion. Full length articles of relevant abstracts were reviewed for inclusion. Bibliographies of the full length articles were also searched for other potential studies and full length articles were retrieved.

Outcomes data were extracted by two reviewers (HE, RL) using prearranged summary tables. Data extraction for preclinical studies included study design, animal model, type of SC used, sample size, and outcomes measured. For the clinical studies, study type, sample size, potential biases, AVN classification, AVN etiology, SC dose and cell type, and outcomes measured were recorded.

Results
=======

Study selection
---------------

We identified 215 abstracts using our electronic search. Thirty-four met the initial screening inclusion criteria and the full-length articles were retrieved and reviewed. Following the full-length reviews, 16 studies (11 preclinical, 5 clinical) met our inclusion criteria and were retained for this review. Eighteen studies were excluded: 3 were review articles \[[@B18]-[@B20]\], one was a surgical technique article \[[@B21]\], 3 articles were early/pilot results which were subsequently included in future articles \[[@B7],[@B16],[@B22]\], 6 articles examined SC treatment in conjunction with therapies other than CD (i.e. vascularized fibula) \[[@B23]-[@B28]\], two articles used SC transplanted intravenously instead of by CD \[[@B13],[@B29]\], 1 article examined prevention of AVN not treatment \[[@B5]\], and two articles included patients with post collapse AVN of the FH \[[@B1],[@B15]\] (Figure [1](#F1){ref-type="fig"}).

![Search, screening and selection of articles for review.](1471-2474-15-156-1){#F1}

Preclinical study characteristics
---------------------------------

### Study design

All preclinical studies utilized an animal model (8 rabbit \[[@B6],[@B10],[@B17],[@B30]-[@B34]\], 2 dog \[[@B11],[@B12]\] and 1 sheep model \[[@B4]\]). AVN was induced using methylprednisolone injection in 6 of the 11 studies \[[@B6],[@B10],[@B30]-[@B32],[@B34]\]. One model utilized liquid nitrogen to create AVN of the FH \[[@B17]\]. Three studies utilized a femoral neck osteotomy to induce AVN \[[@B11],[@B12],[@B33]\]. One study induced AVN by instillation of ethanol to the FH via CD \[[@B4]\].

### Stem cell treatment

The type of SC implanted were variable yet may be classified into three groups: 1) bone marrow derived stem cells -- concentrated, un-cultured bone marrow mononuclear cells (BMMNC), fresh (1 study) \[[@B6]\] or cryopreserved (1 study) \[[@B32]\], and mesenchymal stem cells obtained post BMMNC culture (4 studies) \[[@B11],[@B12],[@B30],[@B33]\]; 2) adipose derived stem cells (2 studies) \[[@B10],[@B34]\]; 3) other -- peripheral blood hematopoietic SC (1 study) \[[@B17]\], cultured endothelial progenitor cells (EPC) (1 study) \[[@B31]\], and human immature dental pulp SC (1 study) \[[@B4]\] (Table [1](#T1){ref-type="table"}).

###### 

Preclinical study characteristics and results

            **Study**             **Animal model**   **Stem cell therapy**   **Results**                              
  ------------------------------ ------------------ ----------------------- ------------- ------- ----- ----- ------- -----
      Wen et al. \[[@B30]\]            Rabbit              BMMNC-MSC             +ve       +ve\*   \--   \--    +ve    +ve
       Sun et al. \[[@B6]\]            Rabbit                BMMNC              +ve\*      +ve\*   \--   \--   +ve\*   \--
      Yan et al. \[[@B12]\]             Dog                BMMNC-MSC            +ve\*       \--    \--   \--    \--    \--
     Feitosa et al. \[[@B4]\]          Sheep           hIDPSC, BMMNC-MSC         +ve        \--    \--   \--    \--    \--
   Abudusaimi et al. \[[@B10]\]        Rabbit                ADSC                +ve        \--    \--   \--   +ve\*   \--
    Aimaiti et al. \[[@B34]\]          Rabbit                ADSC                +ve        +ve    \--   \--   +ve\*   \--
      Song et al. \[[@B17]\]           Rabbit                PBSC                +ve       +ve\*   \--   \--    \--    \--
      Sun et al. \[[@B31]\]            Rabbit                 EPC               +ve\*      +ve\*   \--   \--    \--    \--
      Hang et al. \[[@B11]\]            Dog                BMMNC-MSC            +ve\*      +ve\*   +ve   +ve    \--    \--
      Wen et al. \[[@B33]\]            Rabbit              BMMNC-MSC             +ve        \--    \--   \--    \--    \--
      Xie et al. \[[@B32]\]            Rabbit               cBMMNC              +ve\*      +ve\*   \--   \--   +ve\*   \--

BMMNC-MSC = mesenchymal stem cells obtained post bone marrow mononuclear cell culture, hIDPSC = human immature dental pulp stem cells, ADSC = adipose derived stem cells, PBSC = peripheral blood stem cells, EPC = endothelial progenitor cells, cBMMNC = cryoperserved bone marrow mononuclear cells, +ve = positive effect compared to controls, −ve = negative effect compared to controls, \-- = not measured, \* = statistically significant (p \< 0.05).

### Histologic analysis

All preclinical studies performed a histologic evaluation of the FH's after SC treatment, examining for osteogenesis. In addition, 5 of the studies performed a quantitative histomorphometric analysis for osteogenesis \[[@B6],[@B11],[@B12],[@B31],[@B32]\]. Seven studies examined the FH's for neovascularization \[[@B6],[@B11],[@B17],[@B30]-[@B32],[@B34]\].

### Imaging analysis

Six of the 11 studies used a variety of imaging techniques to evaluate bone formation \[[@B6],[@B10],[@B11],[@B30],[@B32],[@B34]\]. Wen et al. used computed tomography (CT), magnetic resonance imaging (MRI), and CT perfusion imaging to evaluate the effectiveness of autologous cultured bone marrow SC therapy \[[@B30]\]. Abudusaimi et al., Xie et al. and Aimaiti et al. used micro CT scan to evaluate bone volume, bone mineral density and trabecular volume \[[@B10],[@B32],[@B34]\]. Sun et al. used micro CT angiography to evaluate angiogenesis \[[@B6]\]. Hang et al. used single photon emission computed tomography (SPECT) and radiographs to evaluate bone density and FH shape \[[@B11]\].

Preclinical study findings
--------------------------

### Histology (11 studies)

Nine studies reported an increase in bone formation in the SC treatment group compared to CD alone \[[@B4],[@B6],[@B10]-[@B12],[@B31]-[@B34]\] and two studies reported an increase in bone formation compared to no treatment \[[@B17],[@B30]\]. In the 5 studies that performed a quantitative histomorphometric analysis, all 5 studies reported significantly increased bone formation (p \< 0.05) following SC therapy versus CD alone \[[@B6],[@B11],[@B12],[@B31],[@B32]\].

Five studies performing a histologic assessment of neovascularization following SC treatment found improvement (p \< 0.05) in the SC treatment groups compared to CD alone \[[@B6],[@B11],[@B30]-[@B32]\]. One study found higher levels of neovascularization compared to no treatment \[[@B17]\]. One study did not perform statistical analysis but reported higher levels of neovascularization \[[@B34]\] (Table [1](#T1){ref-type="table"}).

### Imaging (6 studies)

On CT imaging, Wen et al. found that the SC group had imaging that closely resembled the normal hip in comparison to CD alone \[[@B30]\]. On MRI imaging they found decreased FH necrosis volume compared to no treatment, and on CT perfusion imaging they found blood volume to be similar to normal hips (no statistics reported) \[[@B30]\]. Abudusaimi et al., Xie et al. and Aimaiti et al. found significantly higher bone volume, bone mineral density and trabecular volume in the SC group compared to CD alone (p \< 0.05) on micro CT \[[@B10],[@B32],[@B34]\].

Sun et al. performed micro CT angiography and found improved angiogenesis (p \< 0.05) \[[@B6]\]. Hang et al. found that the CD only group had decreased uptake of radioactivity on SPECT compared to SC treatment group, indicative of worse perfusion \[[@B11]\]. Radiographs also revealed that the CD only group had worse results, with irregular articular surfaces and heterogenous density of the FH in comparison to the SC group (no statistics reported) \[[@B11]\] (Table [1](#T1){ref-type="table"}).

Clinical study characteristics
------------------------------

### Study design

The clinical studies included two randomized control trials (RCT) \[[@B8],[@B14]\], one non randomized comparison study (nRCT) \[[@B2]\], and two case series \[[@B9],[@B35]\]. The length of follow up for the RCTs was 24 months \[[@B14]\], and 60 months \[[@B8]\]. The nRCT had a follow up of 60 months \[[@B2]\]. The case series' examined outcomes at an average follow up of 27.6 months (12--40 months) \[[@B9]\], and 13 years (8--18 years) \[[@B35]\].

### Sample size

Sample size (n) was recorded as number of hips. Combined, the 5 studies comprised 763 hips. Across studies, n varied from a minimum of 24 \[[@B2]\] to a maximum of 534 \[[@B35]\] (Table [2](#T2){ref-type="table"}). None of the studies reported a power calculation.

###### 

Clinical Study Characteristics

           **Study**             **Type**     **n**   **Initial AVN class**                                              **AVN etiology (\# of hips)**                                              **Treatment protocol**
  ---------------------------- ------------- ------- ----------------------- --------------------------------------------------------------------------------------------------------------------- ------------------------
   Hernigou et al. \[[@B35]\]   Case series    534          Ficat 1-2                                steroid (101), ethanol (150), sickle cell (166), not specified (117)                             Concentrated BMMNC
     Wang et al. \[[@B9]\]      Case series    50           ARCO 1-2                                              steroid (25), ethanol (19), idiopathic (6)                                          Concentrated BMMNC
    Gangji et al. \[[@B2]\]        nRCT        24           ARCO 1-2                                               steroid (20), ethanol (2), idiopathic (2)                                          Concentrated BMMNC
     Sen et al. \[[@B14]\]          RCT        51           ARCO 1-2                          trauma (17), steroid (20), ethanol 8), idiopathic (2), pregnancy (2), Cushings (2)                      Concentrated BMMNC
     Zhao et al. \[[@B8]\]          RCT        97          ARCO 1C-2C         trauma (20), steroid (24), ethanol (19), Caisson (11), idiopathic (30) *(some patients had more than one etiology)*       Cultured BMMNC

BMMNC = bone marrow mononuclear cells, n = number of hips, ARCO = Association Research Circulation Osseous classification, nRCT = non randomized control trial, RCT = randomized control trial.

### Avascular necrosis classification and etiology

Combined, the studies included patients with the following etiologies for AVN: trauma \[[@B8],[@B14]\], steroid use \[[@B2],[@B8],[@B9],[@B14],[@B35]\], ethanol use \[[@B2],[@B8],[@B9],[@B14],[@B35]\], pregnancy \[[@B14]\], Cushing's disease \[[@B14]\], Caisson disease \[[@B8]\], sickle cell disease \[[@B34]\], and idiopathic \[[@B2],[@B8],[@B9],[@B14]\]. Hernigou et al. did not specify the cause of AVN for 117 of 534 hips in their case series \[[@B35]\] (Table [2](#T2){ref-type="table"}). The severity of AVN was classified using two grading systems across the 5 studies. Four of the studies utilized the Association Research Circulation Osseous (ARCO) classification \[[@B2],[@B8],[@B9],[@B14]\] and included patients with an ARCO classification of 1--2 (precollapse). One study used the Ficat classification, and included patients in Ficat stage 1 or 2 \[[@B35]\] (Table [2](#T2){ref-type="table"}).

### Stem cell treatment protocol

Four studies utilized concentrated BMMNC harvested from the iliac crests of each patient as their SC treatment \[[@B2],[@B9],[@B14],[@B35]\]. Zhao et al. used cultured autologous BMMNC harvested from the proximal femur of each patient as their SC treatment \[[@B8]\]. After bone marrow was harvested, in vitro expansion of the mesenchymal SC was performed for 2 weeks prior to reimplantation. SC treatment was performed in conjunction with CD for all clinical studies (Table [2](#T2){ref-type="table"}).

### Stem cell dose

SC dose was measured using a variety of methods - total mononucleated cell count (TMNCC), CD34+ cell count, number of fibroblast colony forming units (F-CFU) and total mesenchymal SC count (TMSCC). TMNCC is a measure of all the nucleated cells including mature nucleated cells and mesenchymal SC. CD34+ cells are a marker of hematopoeitic precursor cells and F-CFU are a measure of mesenchymal SC (each F-CFU is thought to arise from clonal expansion of mesenchymal SC). TMSCC is an approximate count of the number of SC and was used by Zhao et al. prior to reimplantation of cultured mesenchymal SC \[[@B8]\].

TMNCC was measured in 4 studies and ranged from 5 × 10^8^ to 19 × 10^8^ cells \[[@B2],[@B9],[@B14]\]. CD34+ cell counts were measured in two studies (1.9 × 10^7^ to 5 × 10^7^ cells) \[[@B2],[@B14]\]. F-CFU counts were measured in two studies (mean F-CFU count of 1.76 × 10^3^ to 2.4 × 10^3^) \[[@B2],[@B35]\]. TMSCC was reported in one study (2.0 × 10^6^ cells) \[[@B8]\] (Table [3](#T3){ref-type="table"}).

###### 

Stem cell dose

           **Study**               **TMNCC**       **CD34+ cell count**   **F-CFU**      **TMSCC**
  ---------------------------- ------------------ ---------------------- ------------ ---------------
   Hernigou et al. \[[@B35]\]         \--                  \--            2.4 × 104         \--
     Wang et al. \[[@B9]\]      15.5 × 108 cells           \--               \--            \--
    Gangji et al. \[[@B2]\]      19 × 108 cells      1.9 × 107 cells      1.76 × 104        \--
     Sen et al. \[[@B14]\]       5 × 108 cells        5 × 107 cells          \--            \--
     Zhao et al. \[[@B8]\]            \--                  \--               \--       2 × 106 cells

TMNCC = total mononucleated cell count, F-CFU = fibroblast colony forming units, TMSCC = total mesenchymal stem cell count.

### Examined outcomes

Across studies a variety of patient reported outcomes were reported, including Harris Hip Score (HHS) (4 studies) \[[@B8],[@B9],[@B14],[@B35]\], Lequesne index (1 study) \[[@B2]\], Western Ontario and McMaster Osteoarthritis index (WOMAC) (1 study) \[[@B2]\], and pain visual analog score (VAS) (1 study) \[[@B2]\]. Three studies examined progression to more advanced ARCO stage \[[@B2],[@B8],[@B9]\], and 3 studies examined volume of necrotic lesion by MRI \[[@B2],[@B8],[@B35]\]. Hip survivorship was measured in all 5 studies and was defined as conversion to THA (4 studies) \[[@B2],[@B9],[@B14],[@B35]\], and conversion to THA or need for vascularized bone grafting (1 study) \[[@B8]\]. Two studies reported KM survival curves as part of their hip survivorship analysis \[[@B2],[@B14]\].

Clinical study results
----------------------

### Patient reported outcomes (5 studies)

Four of the studies reported HHS \[[@B8],[@B9],[@B14],[@B35]\]. Zhao et al. found a statistically significant increase in HHS 60 months following SC therapy compared to CD only in patients with ARCO stage 1C/2B/2C (p \< 0.05, raw score not reported), and a trend for ARCO stage 2A (p = 0.06, raw score not reported) \[[@B8]\]. Sen et al. found a statistically significant difference in HHS for the SC treated patients compared to CD only at 12 months follow up (83.65 ± 8.04 vs. 76.68 ± 13.86, p \< 0.05) \[[@B14]\]. At 24 months, overall HHS was not significantly improved between the two groups (82.42 ± 9.63 vs. 77.39 ± 16.98, p = 0.09), but the pain and deformity domains of the HHS were still in favor of the SC therapy group (p \< 0.05, raw score not reported) \[[@B14]\]. Wang et al. reported statistically significant (p \< 0.05) improvements in HHS score at an average of 27.6 months post SC treatment for patients in ARCO stage 1/2A/2B/2C, from 90 ± 0.06 to 96 ± 0.06, 78.6 ± 1.02 to 92.5 ± 1.22, 68.2 ± 6.16 to 82.6 ± 8.23, and 67.8 ± 11.2 to 77.9 ± 15.15 respectively \[[@B9]\]. Hernigou et al. reported HHS on patients that had not progressed to having THA (420 of 534 hips) \[[@B35]\]. They reported HHS of 70 preoperatively and 88 post SC treatment at an average of 13 years follow up (no p value reported) \[[@B35]\].

Gangji et al. examined 3 patient reported outcomes: Lequesne index, VAS and WOMAC \[[@B2]\]. The SC treatment group had improved Lequesne index compared to CD group (SC group = 4.8 ± 1.8, CD group Lequesne index not reported, p = 0.03), and improved VAS (SC group = 20.8 ± 7.7, CD group VAS not reported, p = 0.009). WOMAC scores were not significantly different between the groups (raw scores not reported, p = 0.091) \[[@B2]\] (Table [4](#T4){ref-type="table"}).

###### 

Clinical study results for stem cell therapy

  **Study**                    **Patient reported outcomes**   **Progression**                                                       **Lesion volume**                                **Hip survivorship**                                                                                                                                                                                 
  ---------------------------- ------------------------------- --------------------------------------------------------------------- ------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------
                               Outcome                                                                                                                                                                                                                                                                                                                                                      
  Hernigou et al. \[[@B35]\]   HHS (13 years)                  Improved compared to baseline score (88 vs 70)\^                                                                       Decreased lesion volume (12 cm^3^ vs 26 cm^3^)\^                                                                                                                                                     17.6% conversion rate to THA at 13 years follow up
  Wang et al. \[[@B9]\]        HHS                             Improved compared to baseline score (83.7 ± 10.34 vs 71.2 ± 6.56)\*   23.7% rate of progression to higher ARCO class                                                                                                                                                                                                        11.8% conversion to THA at 27.6 months
  Gangji et al. \[[@B2]\]      Lequesne index                  Improved compared to CD (SC group 4.8 ± 1.8, CD group NR)\*           Decreased progression (23.1% vs 72.7%)\*         Decreased lesion volume at 24 months (SC group volume decreased 42%, CD group volume decreased 1%)\*, no improvement at 60 months (SC group volume decreased 42%, CD group volume decreased 22%)\#   No improvement in hip survivorship (57.2 months vs 50.2 months)
                               VAS pain                        Improved compared to CD (SC group 20.8 ± 7.7, CD group NR)\*                                                                                                                                                                                                                                                                 
                               WOMAC                           No improvement compared to CD (raw score NR)                                                                                                                                                                                                                                                                                 
  Sen et al. \[[@B14]\]        HHS (12 months)                 Improved compared to CD (83.65 ± 8.04 vs 76.68 ± 13.86)\*                                                                                                                                                                                                                                                                   Improved hip survivorship (51.85 ± 0.15 weeks vs. 46.62 ± 2.34 weeks)\*
  Zhao et al. \[[@B8]\]        HHS ARCO 1C,2B,2C (60 months)   Improved compared to CD (raw score NR)\*                              Decreased progression (3.8% vs. 22.7%)\*         Decreased lesion volume in ARCO 2B (6.5% vs 13.3% of FH), and ARCO 2C (13.8% vs 29.3%)\*                                                                                                             Decreased rate of conversion to THA/vascularized bone graft in the SC group compared to CD (3.7% vs. 22.7%)\*

HHS = Harris Hip Score, ARCO = Association Research Circulation Osseous classification, VAS = visual analog scale pain score, WOMAC = Western Ontario and McMaster Universities Osteoarthritis index, \^ = no statistics reported, \* = p \< 0.05, \# = p = 0.06, CD = core decompression, NR = not reported, FH = femoral head, THA = total hip arthroplasty.

### Progression of avascular necrosis (3 studies)

Two of 3 studies found a significant decrease in the proportion of patients progressing to ARCO stage 3 or 4 following SC treatment compared to CD only treatment, 60 months post procedure (p \< 0.05) \[[@B2],[@B8]\]. Zhao et al. reported a decrease from 22.7% (CD group) to 3.7% (SC group) \[[@B8]\] and Gangji et al. reported a decrease from 72.7% (CD group) to 23.1% (SC group) \[[@B2]\]. Gangji et al. also performed a KM survival analysis with progression to ARCO stage 3 as the end point, and found a significantly longer (p \< 0.05) time to progression to ARCO stage 3 in the SC group compared to CD \[52.2 months (43.35 - 60.96, 95% confidence interval (CI)) vs 26.5 months (13.2 - 39.74, 95% CI)\] \[[@B2]\]. In their case series, Wang et al. reported a 22% rate of progression to higher ARCO stage (for hips in ARCO stage 1 or 2 before SC treatment) at an average follow up of 27 months \[[@B9]\] (Table [4](#T4){ref-type="table"}).

### Volume of necrotic lesion (3 studies)

Zhao et al. reported a significant decrease in lesion volume in SC treated hips compared to CD only treated hips with a pretreatment ARCO stage of 2B and 2C (ARCO 2B = 6.5% vs 13.3% of FH, ARCO 2C = 13.8% vs 29.3% of FH, p \< 0.05) at 60 months post treatment \[[@B8]\]. Gangji et al. reported a significant decrease in lesion volume after SC treatment compared to CD only at 24 months follow up (SC group volume decreased 42%, CD group volume decreased 1%, p \< 0.05), and a trend towards decreased lesion volume at 60 months (SC group volume decreased 42%, CD group volume decreased 22%, p = 0.06) \[[@B2]\]. Hernigou et al. reported on lesion volume in 371 of 534 hips in their case series \[[@B35]\]. They found a decrease in lesion size from 26 cm^3^ to 12 cm^3^ at an average of 12 years follow up (no statistical analysis reported) \[[@B35]\] (Table [4](#T4){ref-type="table"}).

### Hip survivorship (5 studies)

Four studies examined conversion rate to THA \[[@B2],[@B9],[@B14],[@B35]\]. Sen et al. performed KM hip survival analysis and they found the SC treatment group to have significantly longer hip survival compared to CD alone \[51.85 weeks (51.54 - 52.15, 95% CI) vs 46.72 weeks (42.13 - 51.31, 95% CI), log rank test 4.44 p = 0.0351\] \[[@B14]\]. Gangji et al's nRCT found no significant difference in rate of conversion to THA between SC treatment and CD alone at 60 months of follow up (SC group: 14.3%, CD only group: 27.3%, p \> 0.05) \[[@B2]\]. They also performed a KM survival analysis and found no significant difference in time to THA between the two groups \[mean time to THA - SC group: 57.2 months (53.48--60.97 95% CI), CD only group: 50.2 months (40.24--60.13 95% CI), log rank test p = 0.42\] \[[@B2]\]. Hernigou et al. found a 17.6% conversion rate in their series over an average follow up of 13 years \[[@B35]\], and Wang et al. found a conversion rate of 12% over an average follow up of 27 months \[[@B9]\].

Zhao et al. found a significant decrease in rate of conversion to THA or need for vascularized bone grafting in the SC group compared to CD alone (3.7% vs. 22.7%, p \< 0.05) \[[@B8]\] (Table [4](#T4){ref-type="table"}).

Discussion
==========

This review systematically examined the current literature on SC therapy for the treatment of early stage (precollapse) AVN of the FH including clinical and preclinical studies. Preclinical studies yielded encouraging results for treatment of AVN of the FH with SC. Although the source of SC varied among studies, SC treatment of AVN uniformly demonstrated improvements in osteogenesis and vascularization. All 11 studies showed positive effects with respect to bone formation in groups treated with SC. Furthermore, reported X-ray, SPECT, CT and MR outcomes from all studies favoured the SC treatment group. Bone marrow was the most common source of SC but other sources such as adipose and dental pulp were identified. SC isolated from dental pulp represents a relatively new treatment option with noteworthy potential for use in orthopaedics \[[@B4]\]. Adipose derived SC are another potential alternative to SC from bone marrow. Advantages of adipose derived SC include abundance, ease of isolation, rapid expansion, and multipotency \[[@B10]\].

Despite positive results, relevance of animal models described in preclinical studies should be considered. Corticosteroid and liquid nitrogen induced AVN of the FH are widely recognized means for induction of AVN in numerous animal models; both lead to ischemic conditions within the FM and eventual osseous infarction producing changes phenotypically similar and clinically relevant to human disease \[[@B36]\]. Some studies, however, have addressed the significance of larger animal models, particularly with respect to translational medicine, as they may better replicate conditions in human AVN. An ovine model of AVN of the FH may better reflect articulation in early-stage human AVN as compared to other disease models \[[@B4]\]. For liquid nitrogen induced disease, the bone defect produced, which is non-negligible in animals with small diameter FHs, has been proposed as a limitation due to its absence from human pathology. This has led some researchers to reject use of this method on rabbits \[[@B37]\].

Results of clinical studies were also encouraging. In our review, the clinical studies used CD as a means for implanting SC directly into the necrotic region of the FH, in the form of a cell suspension. CD works by decreasing intra-osseous pressure and improving circulation and vascularization \[[@B9]\]. Used alone, however, CD exhibits inconsistent outcomes including poor lesion reconstruction, ultimately leading to FH collapse \[[@B9],[@B14]\]. The progression of AVN of the FH occurs in consequence of a limited capacity for articular tissue self-repair \[[@B3],[@B11],[@B14]\], including decreased osteogenesis \[[@B11],[@B14]\] and vascularization \[[@B3]\]. This may occur as a result of inadequate numbers of progenitor cells in the proximal femur of patients with AVN of the FH \[[@B38]\]. It is thought that SC implanted into the necrotic region of the FH work to repopulate the low numbers of progenitor cells \[[@B20]\]. Pluripotent, mesenchymal SC differentiate into various cell types, namely osteoblasts, thereby improving repair mechanisms and potentially reversing damage to bone \[[@B11],[@B12],[@B14]\]. In addition to directly increasing bone formation by differentiating into osteoblasts, it is hypothesized that mesenchymal SC have an indirect effect by the expression of cytokines which influence osteogenesis and neovascularization \[[@B39],[@B40]\]. In general, clinical studies reported improvements in patient reported outcomes for those treated with SC; notably, the HHS. Similarly, studies that examined progression to more advanced disease, and lesion volume reported improvements for the SC treatment group. Participants treated with SC did not experience consistent improvements in hip survivorship across studies. None of the studies using a comparative group found worse outcomes for SC treatment.

Considerable variations and inconsistent reporting among clinical studies were observed regarding the dose of SC, etiology of AVN, lesion size, and severity/classification of disease making comparisons between studies challenging. However, there are currently limited numbers of clinical studies addressing SC therapy for treatment of AVN of the FH, and even fewer addressing early-stage disease and administration of SC by CD. Accordingly, we were unable to perform meta-analysis on study results. Quantitative assessment will be a prerequisite to making definitive conclusions on vital therapy-related factors such as SC dose and quality.

Standardization of SC dose has proven difficult due to a lack of uniformly accepted, reliable cell markers which can be used to identify mesenchymal SC \[[@B39]\]. However, the dose of SC used has been reported to impact disease outcome \[[@B7]\]. Both SC dose and quality are also known to affect their clinical potential. Density of SC transplanted to the necrotic FH was shown to affect the rate of osteogenesis, and thereby bone repair \[[@B12]\]. Quality of transplanted cells affects their proliferative capacity \[[@B41]\]. Prior to routine use of combined SC/CD therapy, defined standards of SC dose and quality, such as CD34+ or CFU counts \[[@B42]\], will likely have to be set in order to accurately evaluate the effect of each therapy. However, as a result of presently observed inconsistencies, and a paucity of studies in this area, further research, examining both SC dose and quality will be prerequisite to routine clinical use of this therapy.

Though not specifically addressed by studies assessed in this review, the impact on treatment outcome of whether cells were derived from a concentrate or a culture may also represent an area for future research. Pre-clinical and clinical studies included examples of both concentrated and cultured cells. Concentrated cells contain all cells and cell types present in the tissue from which they have been derived, not only SC. Concentrated BMMNC from bone marrow aspirate contain hematopoietic progenitor cells, lymphocytes, leucocytes, in addition to non-hematopoietic cells including MSC, EPC, embryonic-like SC expressing pluripotent markers, and other multipotent or committed cells \[[@B43]\]. Cultured cells, conversely, represent an isolated pool of SC. The comparative regenerative capacity of concentrated vs. cultured cells remains unclear. Despite positive results observed for both treatments within this review, other studies explicitly assessing differences between the two have displayed mixed findings. Use of pure, cultured MSC led to greater improvements in ischemic limb diseases, compared to concentrated BMMNC, in both human and rat models \[[@B44],[@B45]\]. Alternatively, BMMNC use displayed beneficial outcomes in treatment of spinal cord injury when compared to MSC \[[@B46]\]. Cost and feasibility must also be considered when selecting an appropriate treatment. Indeed, cultured cells require greater preparation times and are associated with increased cost \[[@B44],[@B47]\]. Ultimately, the outcomes of concentrated vs. cultured cells should be assessed for the specific treatment of AVN of the FH in order to develop future robust clinical guidelines for cellular intervention in this disease.

Etiologic risk factors of AVN are also known to significantly affect treatment outcomes \[[@B2]\]. It has been demonstrated that the capacity for SC to differentiate into the necessary osteogenic cells for bone repair and remodeling is limited in patients with alcohol and steroid induced AVN of the FH due to differences in the ischemic environment \[[@B12],[@B48]\]. The size of the osteonecrotic lesion is also known to affect overall patient outcome no matter the method of treatment used \[[@B8],[@B49]\]. Future studies should aim to use the same AVN classification system as well as account for AVN etiology and lesion size as potential confounding variables.

Several other reviews \[[@B18],[@B38],[@B50]-[@B53]\] have been published discussing the use of SC for the treatment of AVN of the femoral head. However to our knowledge, ours is the first systematic review that includes data from several recently published clinical trials \[[@B2],[@B8],[@B14]\]. Our review included data from over 700 hips, more than previously published reviews. Additionally, our review included both clinical and pre-clinical studies, furthering the breadth of our review. A limitation of any systematic review is in the quality of the papers available for review. Clinical studies included in our review did not provide sample size and power calculations. Preclinical studies did not always use a classification system to identify stage of AVN of the FH. There were a limited number of comparative trials, and only two RCTs. We included all types of clinical studies, potentially introducing confounding and selection bias. We felt that inclusion of these studies would provide a more comprehensive review of the literature surrounding this topic. Furthermore, meta-analysis was not performed due to the limited number of comparative trials and variable methodology employed in the studies.

Conclusions
===========

AVN of the FH primarily affects younger, working age individuals and thus leads to increased morbidity and functional disability in this population \[[@B13],[@B30]\]. Treatments aimed at halting or delaying progression of disease would provide a welcome alternative to those faced with progression to joint collapse and hip replacement surgery. Combining CD, the most widely used treatment for AVN of the FH to date \[[@B30]\], with SC, could result in a novel long lasting hip preserving treatment option. Pre-clinical studies have demonstrated the potential of SC for reversing the debilitating damage to the femoral head associated with AVN *in vitro*. Current clinical studies have suggested beneficial effects on patient reported outcomes, but definitive conclusions regarding hip survival and disease progression cannot be made. Further, more refined clinical studies are needed to establish the effectiveness of SC treatment in AVN of the FH. Quantitative studies including meta-analyses aimed at addressing SC dose and quality standards will be necessary to make fundamental treatment-related deductions. The effects of concentration and culture based preparatory methods for SC therapy should be compared in the context of treating AVN of the FH in order to establish suitable protocols. Demonstrated improvement in hip survivorship is prerequisite to the future of this treatment.
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